Paul Hudson’s Post

What if we could identify the right patients for our research and development programs in just a matter of minutes?  When Sanofi announced our collaboration with Formation Bio and OpenAI five months ago, I knew good things were coming. Already we are making tangible progress with the introduction of Muse - a first-of-its kind AI powered tool to optimize patient recruitment for clinical trials.  Patients are at the center of all our research and development programs. Without them, we would not be able to turn scientific discoveries into best-in-class medicines and vaccines that improve lives. Muse will give us access to a wider, diverse pool of potential participants so we can more precisely identify the right patients for our research. It’s the perfect example of what we can accomplish by combining the strengths of like-minded partners who see the power of AI in shaping the future of drug development.  Muse is another building block in our ambition to be the first pharma company powered by AI at scale – and the first in a growing pipeline of innovations being created to help us accelerate drug development so we can deliver medical breakthroughs for people around the world.  Learn more about Muse here: https://lnkd.in/e5wfX_WU #AI #innovation #immunoscience 

What if we could identify the right patients for our research and development programs in just a matter of minutes?  When Sanofi announced our collaboration with Formation Bio and OpenAI five months ago, I knew good things were coming. Already we are making tangible progress with the introduction of Muse - a first-of-its kind AI powered tool to optimize patient recruitment for clinical trials.  Patients are at the center of all our research and development programs. Without them, we would not be able to turn scientific discoveries into best-in-class medicines and vaccines that improve lives. Muse will give us access to a wider, diverse pool of potential participants so we can more precisely identify the right patients for our research. It’s the perfect example of what we can accomplish by combining the strengths of like-minded partners who see the power of AI in shaping the future of drug development.  Muse is another building block in our ambition to be the first pharma company powered by AI at scale – and the first in a growing pipeline of innovations being created to help us accelerate drug development so we can deliver medical breakthroughs for people around the world.  Learn more about Muse here: https://lnkd.in/e5wfX_WU #AI #innovation #immunoscience 

What if we could identify the right patients for our research and development programs in just a matter of minutes?  When Sanofi announced our collaboration with Formation Bio and OpenAI five months ago, I knew good things were coming. Already we are making tangible progress with the introduction of Muse - a first-of-its kind AI powered tool to optimize patient recruitment for clinical trials.  Patients are at the center of all our research and development programs. Without them, we would not be able to turn scientific discoveries into best-in-class medicines and vaccines that improve lives. Muse will give us access to a wider, diverse pool of potential participants so we can more precisely identify the right patients for our research. It’s the perfect example of what we can accomplish by combining the strengths of like-minded partners who see the power of AI in shaping the future of drug development.  Muse is another building block in our ambition to be the first pharma company powered by AI at scale – and the first in a growing pipeline of innovations being created to help us accelerate drug development so we can deliver medical breakthroughs for people around the world.  Learn more about Muse here: https://lnkd.in/e5wfX_WU #AI #innovation #immunoscience 

What if we could identify the right patients for our research and development programs in just a matter of minutes?  When Sanofi announced our collaboration with Formation Bio and OpenAI five months ago, I knew good things were coming. Already we are making tangible progress with the introduction of Muse - a first-of-its kind AI powered tool to optimize patient recruitment for clinical trials.  Patients are at the center of all our research and development programs. Without them, we would not be able to turn scientific discoveries into best-in-class medicines and vaccines that improve lives. Muse will give us access to a wider, diverse pool of potential participants so we can more precisely identify the right patients for our research. It’s the perfect example of what we can accomplish by combining the strengths of like-minded partners who see the power of AI in shaping the future of drug development.  Muse is another building block in our ambition to be the first pharma company powered by AI at scale – and the first in a growing pipeline of innovations being created to help us accelerate drug development so we can deliver medical breakthroughs for people around the world.  Learn more about Muse here: https://lnkd.in/e5wfX_WU #AI #innovation #immunoscience 

What if we could identify the right patients for our research and development programs in just a matter of minutes?  When Sanofi announced our collaboration with Formation Bio and OpenAI five months ago, I knew good things were coming. Already we are making tangible progress with the introduction of Muse - a first-of-its kind AI powered tool to optimize patient recruitment for clinical trials.  Patients are at the center of all our research and development programs. Without them, we would not be able to turn scientific discoveries into best-in-class medicines and vaccines that improve lives. Muse will give us access to a wider, diverse pool of potential participants so we can more precisely identify the right patients for our research. It’s the perfect example of what we can accomplish by combining the strengths of like-minded partners who see the power of AI in shaping the future of drug development.  Muse is another building block in our ambition to be the first pharma company powered by AI at scale – and the first in a growing pipeline of innovations being created to help us accelerate drug development so we can deliver medical breakthroughs for people around the world.  Learn more about Muse here: https://lnkd.in/e5wfX_WU #AI #innovation #immunoscience 

OpenAI x Bio   Last week's unveiling of Muse, an AI-tool resulting from OpenAI's collaboration with Sanofi and Formation Bio, highlights the inroads that OpenAI has been making in the biopharma space. OpenAI has been on a biopharma partnering spree, just in the last 6 - 7 months OpenAI partnered with:   - Sanofi & Formation Bio in May (to create Muse a AI tool aimed at expediting patient recruitment in clinical trials) - Moderna in April (to integrate AI across various business functions including R&D, so far resulting in 750 internal AI-tools) - Eli Lilly and Company in June (to leverage GenAI for discovering novel antimicrobials)   Interestingly, all partnerships have quite different AI use cases.

OpenAI x Bio   Last week's unveiling of Muse, an AI-tool resulting from OpenAI's collaboration with Sanofi and Formation Bio, highlights the inroads that OpenAI has been making in the biopharma space. OpenAI has been on a biopharma partnering spree, just in the last 6 - 7 months OpenAI partnered with:   - Sanofi & Formation Bio in May (to create Muse a AI tool aimed at expediting patient recruitment in clinical trials) - Moderna in April (to integrate AI across various business functions including R&D, so far resulting in 750 internal AI-tools) - Eli Lilly and Company in June (to leverage GenAI for discovering novel antimicrobials)   Interestingly, all partnerships have quite different AI use cases.